Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease

Nat Commun. 2023 Oct 25;14(1):6769. doi: 10.1038/s41467-023-42247-w.

Abstract

Post-infectious conditions present major health burdens but remain poorly understood. In Chagas disease (CD), caused by Trypanosoma cruzi parasites, antiparasitic agents that successfully clear T. cruzi do not always improve clinical outcomes. In this study, we reveal differential small molecule trajectories between cardiac regions during chronic T. cruzi infection, matching with characteristic CD apical aneurysm sites. Incomplete, region-specific, cardiac small molecule restoration is observed in animals treated with the antiparasitic benznidazole. In contrast, superior restoration of the cardiac small molecule profile is observed for a combination treatment of reduced-dose benznidazole plus an immunotherapy, even with less parasite burden reduction. Overall, these results reveal molecular mechanisms of CD treatment based on simultaneous effects on the pathogen and on host small molecule responses, and expand our understanding of clinical treatment failure in CD. This link between infection and subsequent persistent small molecule perturbation broadens our understanding of infectious disease sequelae.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Chagas Disease* / drug therapy
  • Chagas Disease* / parasitology
  • Disease Progression
  • Heart
  • Nitroimidazoles* / pharmacology
  • Nitroimidazoles* / therapeutic use
  • Trypanocidal Agents* / pharmacology
  • Trypanocidal Agents* / therapeutic use
  • Trypanosoma cruzi*

Substances

  • benzonidazole
  • Trypanocidal Agents
  • Nitroimidazoles